X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PANACEA BIOTECH NATCO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 23.7 172.3 13.8% View Chart
P/BV x 17.9 3.8 468.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
NATCO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs877149 589.8%   
Low Rs42482 514.6%   
Sales per share (Unadj.) Rs223.484.1 265.5%  
Earnings per share (Unadj.) Rs31.1-18.3 -169.7%  
Cash flow per share (Unadj.) Rs40.3-6.7 -601.2%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.583.7 262.2%  
Shares outstanding (eoy) m33.0761.25 54.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.4 212.0%   
Avg P/E ratio x20.9-6.3 -331.7%  
P/CF ratio (eoy) x16.1-17.2 -93.6%  
Price / Book Value ratio x3.01.4 214.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5047,074 304.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,1281,449 77.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m7,3895,154 143.4%  
Other income Rs m167100 167.4%   
Total revenues Rs m7,5565,254 143.8%   
Gross profit Rs m1,793-766 -234.0%  
Depreciation Rs m304711 42.8%   
Interest Rs m3661,503 24.4%   
Profit before tax Rs m1,290-2,881 -44.8%   
Minority Interest Rs m4611 428.7%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m30917 1,837.5%   
Profit after tax Rs m1,027-1,121 -91.6%  
Gross profit margin %24.3-14.9 -163.2%  
Effective tax rate %23.9-0.6 -4,103.7%   
Net profit margin %13.9-21.8 -63.9%  
BALANCE SHEET DATA
Current assets Rs m3,6813,810 96.6%   
Current liabilities Rs m3,1238,365 37.3%   
Net working cap to sales %7.6-88.4 -8.6%  
Current ratio x1.20.5 258.8%  
Inventory Days Days89156 57.5%  
Debtors Days Days5967 87.3%  
Net fixed assets Rs m7,68514,480 53.1%   
Share capital Rs m33161 539.5%   
"Free" reserves Rs m6,670903 738.5%   
Net worth Rs m7,2595,127 141.6%   
Long term debt Rs m9555,832 16.4%   
Total assets Rs m11,95719,433 61.5%  
Interest coverage x4.5-0.9 -493.4%   
Debt to equity ratio x0.11.1 11.6%  
Sales to assets ratio x0.60.3 233.0%   
Return on assets %11.72.0 593.4%  
Return on equity %14.2-21.9 -64.7%  
Return on capital %20.73.6 569.9%  
Exports to sales %39.424.5 160.5%   
Imports to sales %5.710.2 56.0%   
Exports (fob) Rs m2,9081,264 230.1%   
Imports (cif) Rs m421525 80.3%   
Fx inflow Rs m3,4451,539 223.8%   
Fx outflow Rs m703942 74.6%   
Net fx Rs m2,743597 459.2%   
CASH FLOW
From Operations Rs m1,440599 240.4%  
From Investments Rs m-1,089-438 248.7%  
From Financial Activity Rs m-353-303 116.6%  
Net Cashflow Rs m-1-141 1.1%  

Share Holding

Indian Promoters % 52.0 74.5 69.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.6 1,306.7%  
FIIs % 16.6 1.3 1,279.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 23.6 110.2%  
Shareholders   25,395 10,259 247.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  CIPLA  ABBOTT INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS